Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Dennis Yiannakis"'
Publikováno v:
Cancers, Vol 15, Iss 2, p 537 (2023)
George Papanikolaou is famously quoted as saying “the first observation of cancer cells in the smear of the uterine cervix gave me one of the greatest thrills I ever experienced during my scientific career” [...]
Externí odkaz:
https://doaj.org/article/8f226c4875d24b089f87cbaae0ccf363
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 1, Pp 29-32 (2014)
A 48-year-old woman with a positive BRCA1 gene mutation was diagnosed with stage 3b high-grade ovarian endometrioid carcinoma. She was treated with adjuvant carboplatin at a dose of 740 mg (AUC 6) in 3-weekly cycles. Five days after her fifth cycle o
Externí odkaz:
https://doaj.org/article/4d4d2d8358bf4535999c91581e7cc2f2
Autor:
Sadaf Ghaem-Maghami, Jo Morrison, Sarah Williams, Stuart Rundle, Tracie Miles, Bruce Ramsay, Christina Fotopoulou, Andrew Nordin, Dennis Yiannakis, Jonathan A. Ledermann, Ranjit Manchanda, Sarah Coleridge, Shibani Nicum, Rebecca Bowen, Agnieszka Michael, Hilary Maxwell, Rick Clayton, Sudha S Sundar, Alexandra Taylor, Nicholas J Wood
Publikováno v:
International Journal of Gynecologic Cancer. 32:9-14
During the COVID-19 pandemic, pressures on clinical services required adaptation to how care was prioritised and delivered for women with gynecological cancer. This document discusses potential ‘salvage’ measures when treatment has deviated from
Publikováno v:
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. 27(2)
The aim of the study was to determine level of agreement between RTOG Conformity Index (RTOG-CI), Paddick Conformity Index (PCI) and Prescription Dose Spillage (PDS) in describing lung stereotactic ablative radiotherapy (SABR) plan conformity; to elu
Publikováno v:
Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 809:43-49
Auranofin, an organogold compound classified as an anti-rheumatic agent is under phase 2 clinical trials for re-purposing to treat recurrent epithelial ovarian cancer. We have reported earlier that Breast cancer 1, early onset (BRCA1) mutant ovarian
Publikováno v:
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. :8-15
Auranofin, a thioredoxin reductase inhibitor and an anti-rheumatic drug is currently undergoing phase 2 clinical studies for repurposing to treat recurrent epithelial ovarian cancer. Previous studies have established that auranofin exerts its cytotox
Autor:
Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh K B Parmar, Tom Ehlen, Gordon C Jayson, Nick Johnson, Ann Marie Swart, René Verheijen, W Glenn McCluggage, Tim Perren, Pierluigi Benedetti Panici, Gemma Kenter, Antonio Casado, Cesar Mendiola, Gavin Stuart, Nick S Reed, Sean Kehoe, Claes Tropé G., Stephen Dobbs, Sharadah Essapen, P. Hoskins, John Green, E. Gilby, M. Van Baal, Jeremy Twigg, Maria E.L. Van Der Burg, Keith Godfrey, Angel J. Lacave, R. Angioli, Rahul Nath, Kirk Chin, Charles Redman, R. Lotocki, Adeola Olaitan, B. Mosgaard, G. Rustin, Thomas Ind, Mojca Persic, Martin Hogg, J. Van Der Velden, J. Ledermann, Peter Sykes Peter Sykes, Krishnawam Madhavan, P. Kannisto, Vicky Hird, A. Evans, R. Sandvei R., P. Gauthier, D.J. Cruickshank, P.B. Ottevanger, Sheila Pearson, Henry Kitchener, Marcia Hall, P. Bessette, S. Pecorelli, E. Gerdin, Tito Lopes, Andrew Fish, Clare Barlow., K. Van Eygen, A. Floquet, B. Tholander, N. Gul, Robert Gornall, David Luesley, Philip Kirwan, Paul Symonds, Richard Henry, David Poole, Ian McNeish, Mark Hocking, Al Sammaraie, P. Speiser, E. Leblanc, J.A. Green, C.F. De Oliveira, R. Grimshaw, P. Zola, David Parkin, Martin Lamb, Anne Hong, Alan Gillespie, Abdel Hamid, Ahmed Ahmed, M. Plante, B. De Valk, A. Nordin, Andrew Clamp, David Perez, Graham Dark Graham Dark, Michelle Ferguson, Carol MacGregor, Geraldine Skailes, Rachel Jones, G. Cawdell, Simon Leeson, L. Elit, C. Dittrich, W. Gotlieb, John Cullimore, Barbara Crosse, Paul Ridley, Anthony Head, Joaquin Nieto, Saif Awwad, Dirk Brinkmann, Damian Eustace, Andrew Hindley, D. Katsaros, C. Popadiuk, Tome Kristeller, C. Redman, S. Chan, C. Marth, Dennis Yiannakis, Kate Lankaster, Gareth Beynon, Anwar Suhail, Fernando Indrajit, Mary Quigley, Olu Adeyemi, Fiona Lofts, Orla McNally, Amanda Tristam, Martin Lee, R. Counsell, N. Gleeson, A. Papadopoulos, T. Maggino, A. Honkoop, P. Ghatage, J.B. Vermorken, J. De Greve, K. Boman, E Petru, F. Amant
Publikováno v:
Lancet Oncology, 19, 12, pp. 1680-1687
Obstetrical and Gynecological Survey, 74(3), 156-158. Lippincott Williams and Wilkins
MRC CHORUS study investigators 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', The Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7
Vergote, I, Coens, C, Nankivell, M, Kristensen, G B, Parmar, M K B, Ehlen, T, Jayson, G C, Johnson, N, Swart, A M, Verheijen, R, McCluggage, W G, Perren, T, Panici, P B, Kenter, G, Casado, A, Mendiola, C, Stuart, G, Reed, N S & Kehoe, S 2019, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', Obstetrical and Gynecological Survey, vol. 74, no. 3, pp. 156-158 . https://doi.org/10.1097/01.ogx.0000554460.78765.59
Jayson, G 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. ', Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7
Lancet Oncology, 19, 1680-1687
The Lancet Oncology, 19(12), 1680-1687. Lancet Publishing Group
Obstetrical and Gynecological Survey, 74(3), 156-158. Lippincott Williams and Wilkins
MRC CHORUS study investigators 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', The Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7
Vergote, I, Coens, C, Nankivell, M, Kristensen, G B, Parmar, M K B, Ehlen, T, Jayson, G C, Johnson, N, Swart, A M, Verheijen, R, McCluggage, W G, Perren, T, Panici, P B, Kenter, G, Casado, A, Mendiola, C, Stuart, G, Reed, N S & Kehoe, S 2019, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', Obstetrical and Gynecological Survey, vol. 74, no. 3, pp. 156-158 . https://doi.org/10.1097/01.ogx.0000554460.78765.59
Jayson, G 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. ', Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7
Lancet Oncology, 19, 1680-1687
The Lancet Oncology, 19(12), 1680-1687. Lancet Publishing Group
Summary Background Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any prefe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f32bf7e089ed9921db1ad91c3ad4e088
https://hdl.handle.net/2066/200265
https://hdl.handle.net/2066/200265
Publikováno v:
BMJ Case Rep
Ovarian cancer is the second the most common gynaecological malignancy in developed countries. 70% of patients relapse in the first 3 years following debulking surgery and first-line chemotherapy. Niraparib is a poly adenosine diphosphate ribose poly
Publikováno v:
Anti-Cancer Drugs. 18:1227-1230
At present, there is no clear consensus on the most appropriate treatment approach for large cell neuroendocrine carcinoma of the lung. Large cell neuroendocrine carcinoma lesions differ from other nonsmall cell lung carcinomas in that they have a pa
Publikováno v:
Journal of Thoracic Oncology. 2:S700